pemafibrate
Kowa Pharmaceuticals
[]
the prominent trial addresses lowering tg for residual cv risk tg (200-499) tx with pemafibrate vs placebo - it showed no difference in primary or secondary endpts 
ACC Immediate Past-President @ACCintouch #interventionalcardiology #ACCBOT #ACCWIC #ACCLeadership #HealthcareInnovation. #Healthequity Opinions my own.